Keros Therapeutics (NASDAQ:KROS – Free Report) had its price target decreased by Piper Sandler from $40.00 to $15.00 in a report issued on Friday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.
Other research analysts also recently issued reports about the company. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $47.00 to $15.00 in a research report on Friday. Finally, Wells Fargo & Company raised their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.56.
View Our Latest Analysis on Keros Therapeutics
Keros Therapeutics Price Performance
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) earnings per share. As a group, sell-side analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.
Hedge Funds Weigh In On Keros Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in KROS. Point72 Asset Management L.P. lifted its holdings in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after buying an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares in the last quarter. Finally, FMR LLC boosted its position in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Recommended Stories
- Five stocks we like better than Keros Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Differences Between Momentum Investing and Long Term Investing
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.